Polycythemia Vera - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Polycythemia Vera - Pipeline Review, H2 2016

Polycythemia Vera - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Polycythemia Vera - Pipeline Review, H2 2016
Published Aug 17, 2016
86 pages — Published Aug 17, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Polycythemia Vera - Pipeline Review, H2 2016, provides an overview of the Polycythemia Vera pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera
- The report reviews pipeline therapeutics for Polycythemia Vera by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Polycythemia Vera therapeutics and enlists all their major and minor projects
- The report assesses Polycythemia Vera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Polycythemia Vera

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication th

  
Source:
Document ID
GMDHC8360IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Polycythemia Vera Overview71
Therapeutics Development81
  Pipeline Products for Polycythemia Vera Overview81
Polycythemia Vera Therapeutics under Development by Companies91
Polycythemia Vera Pipeline Products Glance103
  Late Stage Products101
  Clinical Stage Products111
  Early Stage Products121
Polycythemia Vera Products under Development by Companies131
Polycythemia Vera Companies Involved in Therapeutics Development1412
  ANP Technologies, Inc.141
  Bristol-Myers Squibb Company151
  F. Hoffmann-La Roche Ltd.161
  Galena Biopharma, Inc.171
  Gilead Sciences, Inc.181
  Italfarmaco S.p.A.191
  Karus Therapeutics Limited201
  miRagen Therapeutics, Inc.211
  Nerviano Medical Sciences S.r.l.221
  Novartis AG231
  PharmaEssentia Corporation241
  Teva Pharmaceutical Industries Ltd.251
Polycythemia Vera Therapeutics Assessment269
  Assessment by Monotherapy Products261
  Assessment by Target272
  Assessment by Mechanism of Action292
  Assessment by Route of Administration312
  Assessment by Molecule Type332
Drug Profiles3541
  anagrelide hydrochloride CR Drug Profile353
  arsenic trioxide Drug Profile383
  dasatinib Drug Profile413
  Drug to Inhibit Ribonucleotide Reductase for Polycythemia Vera and Essential Thrombocythemia Drug Profile441
  givinostat Drug Profile452
  idelalisib Drug Profile478
  KA-1463 Drug Profile551
  M-009 Drug Profile561
  M-012 Drug Profile572
  MGN-4893 Drug Profile591
  momelotinib dihydrochloride Drug Profile605
  NMSP-113 Drug Profile651
  peginterferon alfa-2a Drug Profile662
  ropeginterferon alfa-2b Drug Profile683
  sonidegib phosphate Drug Profile715
Polycythemia Vera Dormant Projects761
Polycythemia Vera Discontinued Products771
Polycythemia Vera Product Development Milestones787
  Featured News &Press Releases781
    May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012781
    May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases781
    Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition791
    Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition801
    Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera811
    Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial821
    Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera821
    Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera831
    Feb 17, 2011: miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for Treatment of Polycythemia Vera841
Appendix852
  Methodology851
  Coverage851
  Secondary Research851
  Primary Research851
  Expert Panel Validation851
  Contact Us851
  Disclaimer861

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Polycythemia Vera - Pipeline Review, H2 2016" Aug 17, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Polycythemia-Vera-Pipeline-Review-H2-2016-2088-16387>
  
APA:
Global Markets Direct - Market Research. (2016). Polycythemia Vera - Pipeline Review, H2 2016 Aug 17, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Polycythemia-Vera-Pipeline-Review-H2-2016-2088-16387>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.